Atossa presents positive PK/tolerability data from Phase 2 EVANGELINE trial of (Z)-endoxifen

ATOSSA THERAPEUTICS, INC.

50% of patients on 80 mg (Z)-endoxifen + goserelin met target plasma Css of 500-1,000 ng/mL.
Tissue Css levels >2x plasma; >90% of patients achieved target tissue levels >500 ng/g.
Ki-67 ≤10% response rate >85% across doses after 4 weeks, indicating antitumor activity.
(Z)-endoxifen well tolerated with no Grade 3-4 toxicities; four gynecologic events in 80 mg groups.
Randomized trial to compare 40 mg + OFS vs exemestane + OFS; recruitment expected to start 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.